Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Expert Opinion On The Use Of Anthracyclines In Patients With Advanced Breast Cancer At Cardiac Risk.

P. Barrett-Lee, J. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, M. Verrill
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Anthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.
This paper references
10.1097/CAD.0B013E328011335E
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin–paclitaxel in metastatic breast cancer patients
C. Nisticò (2007)
Adriamycin cardiotoxicity: a survey of 1273 patients.
C. Praga (1979)
10.1200/JCO.2004.06.022
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
J. Silber (2004)
Refresher corner Preventing the cardiotoxic effects of anthracyclines : from basic concepts to clinical data
Catherine Vergely (2007)
10.1081/CNV-100103136
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
A. Gabizon (2001)
10.1186/1476-7120-5-9
Interference of breast implants with echocardiographic image acquisition and interpretation
M. Movahed (2007)
10.1053/J.SEMINONCOL.2006.04.020
Pathogenesis of cardiotoxicity induced by anthracyclines.
P. Elliott (2006)
10.1200/JCO.2004.03.516
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
E. Perez (2004)
10.1053/EUHJ.2002.3255
Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population.
F. Hobbs (2002)
10.1067/MNC.2003.7
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
I. Mitani (2003)
10.7326/0003-4819-96-2-133
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
Detection and monitoring of cardiotoxicity—what does modern cardiology offer? Support Care Cancer
R Jurcut (2008)
10.1002/14651858.cd005008.pub2
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
E. C. van Dalen (2006)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1093/OXFORDJOURNALS.ANNONC.A010717
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.
J. Gehl (1996)
10.1007/s10549-007-9803-5
The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines
G. Dranitsaris (2007)
10.1634/THEONCOLOGIST.7-SUPPL_6-4
Treatment for anthracycline-pretreated metastatic breast cancer.
J. O'Shaughnessy (2002)
10.1053/J.SEMINONCOL.2005.11.001
Anticancer agents and cardiotoxicity.
R. Ng (2006)
[Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data].
S. Delemasure (2006)
10.1200/JCO.2007.14.5920
The Journal of Clinical Oncology: The Initial Years
J. Bertino (2008)
10.1016/S1043-321X(05)80308-X
Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
Andrew D. Seidman (2006)
10.1200/JCO.1997.15.5.1906
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
L. Gianni (1997)
10.1023/A:1011655503511
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
L. Gianni (2001)
10.1002/14651858.CD003917.pub4
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2011)
10.1053/j.seminoncol.2004.08.006
Cardiac safety of liposomal anthracyclines.
Michael S. Ewer (2004)
10.1136/HEART.88.1.81
Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques
M. T. Meinardi (2002)
10.1002/14651858.CD005006.pub3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)
10.1093/ANNONC/MDM228
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study.
F. Giotta (2007)
Detection and monitoring of cardiotoxicity—what does modern cardiology offer? Support Care Cancer
R Jurcut (2008)
Prevention and management of cardiotoxicity from antineoplastic therapy.
A. Chanan-Khan (2004)
10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V
Acute arrhythmogenicity of doxorubicin administration
J. Steinberg (1987)
10.1517/14740338.5.6.791
Anthracycline cardiotoxicity
R. Jones (2006)
10.1016/j.ejheart.2006.09.007
Monitoring left ventricular function in adults receiving anthracycline‐containing chemotherapy
M. Belham (2007)
10.1093/JNCI/DJK064
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
M. Hooning (2007)
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as firstline therapy for metastatic breast cancer
S Chan (2004)
10.14712/18059694.2019.117
Anthracycline-induced cardiotoxicity.
R. Hrdina (2000)
10.1093/ANNONC/MDF170
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy.
D. Cardinale (2002)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1001/JAMA.285.7.885
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.
R. Yancik (2001)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1200/JCO.1993.11.7.1264
Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.
M. Estorch (1993)
10.1007/s00520-007-0397-6
Detection and monitoring of cardiotoxicity—what does modern cardiology offer?
R. Jurcut (2007)
Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
M. Estorch (1990)
10.1097/00000478-197701010-00002
Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation
M. Billingham (1977)
10.1056/NEJM199506293322602
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
S. Lipshultz (1995)
10.1007/s00392-007-0633-6
Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults
F. Dodos (2007)
10.1016/S0735-1097(00)00748-8
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.
D. Cardinale (2000)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.1016/S0084-3873(08)79268-X
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
M. Cheitlin (2008)
10.1093/ANNONC/MDF231
Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?
T. Suter (2002)
10.1200/JCO.2006.06.5391
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
S. Jones (2006)
10.3109/07357909909021433
Cardiotoxicity of cancer therapy.
K. Tolba (1999)
10.1158/1078-0432.CCR-07-1033
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
B. Bird (2008)
10.1007/s12012-007-0016-2
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
C. Zuppinger (2007)
Cardiotoxicity after Adjuvant Anthracycline-based Chemotherapy and Radiotherapy for Breast Cancer
T. Yau (2005)
10.1517/14656566.8.8.1039
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
E. Barry (2007)
10.1200/JCO.2007.14.8742
Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
M. Ewer (2008)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1016/J.EHJ.2004.06.003
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
J. López-Sendón (2004)
10.1093/ANNONC/MDH393
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
S. Chan (2004)
10.1634/THEONCOLOGIST.12-9-1124
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
G. Mercuro (2007)
10.1016/S0140-6736(07)61865-0
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu (2007)
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel with cyclophosphamide as adjuvant therapy for operable breast cancer
Se Jones (2006)
10.1200/JCO.2005.08.789
Cardiotoxicity of cancer therapy.
Justin D. Floyd (2005)
Annals of Oncology review
(2009)
10.1093/ANNONC/MDF132
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
B. V. Jensen (2002)
Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
A. Nagy (2006)
10.1200/JCO.2007.10.8399
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
M. Piccart-Gebhart (2008)
10.1200/JCO.2007.12.1665
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
H. Mouridsen (2007)
10.1200/JCO.2005.05.827
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
M. Ewer (2005)
10.1093/ANNONC/MDF318
The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage.
I. Goethals (2002)
10.1016/J.JACC.2007.06.037
Early breast cancer therapy and cardiovascular injury.
L. Jones (2007)
10.1002/cncr.10914
Doxorubicin‐paclitaxel
L. Biganzoli (2003)
10.1097/00001813-200606000-00014
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
G. Batist (2006)
10.1093/ANNONC/MDJ034
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
P. Fumoleau (2006)
Left ventricular dysfunction by early troponin I release after high-dose chemotherapy
D Cardinale (2000)
10.1002/14651858.cd003917.pub2
Cardioprotective interventions for cancer patients receiving anthracyclines.
Elvira C. van Dalen (2005)
10.1016/j.jacc.2007.11.060
Early breast cancer therapy and cardiovascular injury.
Laurel J. Steinherz (2008)
10.1007/s10554-006-9145-0
Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction
L. E. Rohde (2006)
10.1080/02841860601156165
Anthracycline-induced chronic cardiotoxicity and heart failure
J. M. Appel (2007)
10.1002/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma
G. Hortobagyi (1989)
National Institute of Clinical Excellence. Management of chronic heart failure in adults in primary and secondary care
(2003)
10.1016/J.EUJE.2005.04.009
Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.
S. Tassan-Mangina (2006)
10.1634/THEONCOLOGIST.8-SUPPL_2-17
Cardiac safety of liposomal anthracyclines.
T. Safra (2003)
10.7326/0003-4819-99-6-745
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
F. Torti (1983)
10.1002/14651858.CD005006.pub4
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2010)
10.1002/14651858.CD005008.pub3
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
Elvira C van Dalen (2009)
10.1200/JCO.1998.16.11.3502
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
M. Ryberg (1998)
10.1200/JCO.1996.14.10.2713
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
F. Holmes (1996)
10.1345/aph.1K359
Monitoring of Anthracycline-Induced Cardiotoxicity
Abigail Jannazzo (2008)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
Cardiotoxicity after Adjuvant Anthracycline-based Chemotherapy and Radiotherapy for Breast Cancer
Tk Yau (2005)
10.7326/0003-4819-126-10-199705150-00020
Anthracycline-induced cardiotoxicity.
Kesavan Shan (1996)
10.3816/CBC.2007.N.017
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
M. Ewer (2007)
10.1586/14737140.6.9.1249
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs
R. Jones (2006)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1200/JCO.2004.06.033
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
O. Hequet (2004)
10.1093/ANNONC/MDI152
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity.
S. Kilickap (2005)
10.1093/OXFORDJOURNALS.ANNONC.A058514
Drugs ten years later: epirubicin.
G. Bonadonna (1993)
10.1007/s10549-006-9470-y
Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter
S. Gandhi (2006)
10.1200/JCO.1999.17.11.3596
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
A. Gennari (1999)
10.1200/JCO.2007.10.9777
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)



This paper is referenced by
Toxic mitochondrial effects induced by "red devil" chemotherapy
C. M. Opperman (2015)
10.1016/S1470-2045(12)70476-X
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
C. Mamot (2012)
10.1016/j.ultrasmedbio.2015.09.008
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients.
D. Mele (2016)
10.1016/j.jcmg.2014.06.007
Noninvasive imaging of cardiovascular injury related to the treatment of cancer.
Suwat Kongbundansuk (2014)
10.1007/s12094-016-1508-y
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
J. Gavilá (2016)
10.25560/10114
Cardiovascular magnetic resonance in cardiomyopathies
G. Smith (2012)
10.3389/fphar.2013.00019
Cardiotoxicity of Cancer Therapeutics: Current Issues in Screening, Prevention, and Therapy
R. Sheppard (2013)
10.1111/tbj.12125
Major Changes in Chemotherapy Regimens Administered to Breast Cancer Patients During 2000–2008 in the Netherlands
Myrthe P.P. Herk‐Sukel (2013)
10.1016/j.lfs.2020.117843
The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know.
Serena L’Abbate (2020)
10.1007/s11764-014-0408-9
Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin
Angel Qin (2014)
10.1007/s12012-016-9365-z
Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy
G. Janbabai (2016)
Powikłania kardiologiczne u pacjentek z niezaawansowanym rakiem piersi po leczeniu uzupełniającym trastuzumabem
Kufel-Grabowska Joanna (2015)
10.1007/978-3-319-70253-7
Side Effects of Medical Cancer Therapy
M. Dicato (2018)
AssociationofAnthracycline-RelatedCardiacHistologicalLesionsWith NADPHOxidaseFunctionalPolymorphisms
Spain Murcia (2013)
Aação do extrato etanólico da casca do pequi na cardiotoxicidade por doxorrubicina em ratos
L. R. Moura (2015)
10.1186/s12885-019-5939-z
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model
Claudia Christowitz (2019)
Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.
E. Curtit (2012)
An investigation into the potential cardioprotective effects of ghrelin in a rat model of chronic doxorubicin-induced cardiotoxicity
T. Goldswain (2017)
10.1101/2020.04.07.029488
Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity – opportunity for repurposed chemotherapy of COVID-19 infection
Maryam Al-Motawa (2020)
10.2459/JCM.0000000000000232
Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction
D. Di Lisi (2016)
10.5604/20828691.1147502
Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity
Ewa Chmielowska (2015)
THE SECRET OF DYING WELL: THE MANY FACES OF CELL DEATH AND ITS RELEVANCE FOR TREATING DISEASES OF OUR TIME
Anna-Mart Engelbrecht (2014)
Cardiomiopatía inducida por antraciclinas en pacientes tratadas por cáncer de mama
L. Alarcón (2012)
10.1016/j.lfs.2019.117234
Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
L. Qiu (2019)
10.1002/9783527800681.CH16
Drug Targeting in Nanomedicine and Nanopharmacy: A Systems Approach
Jingwei Shao (2016)
10.1007/978-94-007-7681-4_20
Cancer Cardiotoxicity and Cardiac Biomarkers
M. Salvatici (2015)
10.7324/japs.2018.8401
Computational Model of Doxorubicin Conjugate with Docosahexaenoic Acid and Integrin α v β 3 Ligand for Anticancer
A. T. Hidayat (2018)
10.18632/oncotarget.15998
Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis
X. Huang (2017)
10.1556/MOnkol.54.2010.4.10
[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
T. Nagykálnai (2010)
10.1634/theoncologist.2012-0239
Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.
A. Cascales (2013)
Deubiquitination : does the answer to cardiotoxicity lie within the ubiquitin proteasome pathway
Temitope Richard Ogundipe (2017)
10.1021/ml3002852
The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
P. Shaul (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar